Abstract 2177P
Background
Immune checkpoint inhibitors (ICI) have revolutionized cancer treatment but they often carry a wide spectrum of immune-related adverse events (irAE), which might preclude treatment continuation. Biomarkers predictive of irAE would be useful to better select and manage patients for ICI therapy.
Methods
This retrospective analysis included patients treated with ≥3 cycles of ICI, regardless of the primary tumour, in a single hospital in Portugal, from January 2017 to December 2022. Data regarding irAE was collected, as well as baseline neutrophil-lymphocyte (NLR), platelet-lymphocyte (PLR) ratios and systemic imune-inflammation index (SII, given by platelets*neutrophils/lymphocytes). Scores were categorized using cutoff values described in literature, as NLR≥3, PLR≥180 and SII≥750. Descriptive analysis was performed using SPSS®. Association between the scores and irAE was analyzed using logistic regression.
Results
141 patients were included. 87% were males and the median age was 66. Most common diagnoses were non-small cell lung cancer (75%) and head and neck cancer (7%) and main ICI were pembrolizumab (53%), durvalumab (18%) and nivolumab (16%), with a 10 cycles median. 137 (97%) patients developed irAE: digestive (24%), cutaneous (20%), flu-like symptoms (12%) and others. 15% had grade ≥3 irAE, leading to ICI suspension in 11%. 55% died during follow-up, most due to disease progression, 1 due to irAE. Median inflammation scores were 3,5 (NLR), 175 (PLR) and 818 (SII). A statistically significant correlation was found between NLR≥3 and gastrointestinal (p 0,007, OR 0,375) and respiratory AE (p 0,023, OR 3,608); SII≥750 and gastrointestinal (p=0,015, OR=0,413), respiratory (p 0,020, OR 0,255) and musculoskeletal AE (p 0,015, OR 0,342); PLR≥180 and hepatic (p 0,045, OR 2,934) and musculoskeletal AE (p 0,045, OR 0,446). There was no correlation with the presence of grade ≥3 AEs nor with survival.
Conclusions
In this study baseline inflammation scores were associated with some irAEs but not with survival as described in literature. These findings support a correlation between systemic inflammation status and tolerability to immunotherapy and show the value of inflammatory scores as potential biomarkers of irAE.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
ULS Matosinhos - Hospital Pedro Hispano.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2184TiP - Extensive cardiovascular characterization and follow-up of patients receiving immune checkpoint inhibitors: A prospective multicenter study
Presenter: Danielle Delombaerde
Session: Poster session 07
2185TiP - Belgian FORX trial: FOod interventions to Reduce immunotherapy toXicity
Presenter: Marthe Verhaert
Session: Poster session 07
2186P - KN046 in patients with thymic carcinoma: A prospective, single-arm, multi-centre, phase II study
Presenter: Wentao Fang
Session: Poster session 07
2187P - Efficacy and safety of gemcitabine as maintenance treatment in unresectable malignant pleural mesothelioma: A phase II randomized study
Presenter: Mohamed Emam Sobeih
Session: Poster session 07
2188P - First-line combination of toripalimab and chemotherapy in advanced thymic carcinoma: A prospective, single-arm, phase II trial
Presenter: hui'yang shi
Session: Poster session 07
2189P - Combining SBRT with GM-CSF and Peg-IFNα to induce abscopal effects in previously treated patients with stage IV thymic tumors
Presenter: Boyan Wang
Session: Poster session 07
2190P - First-line atezolizumab in combination with platinum etoposide in patients with metastatic lung large cell neuroendocrine carcinoma (LCNEC)
Presenter: Georgios Evangelou
Session: Poster session 07
2191P - Real-world outcomes of patients with malignant pleural mesothelioma (MPM) treated with combination nivolumab and ipilimumab in the first- or later line setting
Presenter: Sabine Schmid
Session: Poster session 07
2192P - Quality of life (QoL) of patients (pts) with advanced malignant pleural mesothelioma (aMPM) treated in a real-world setting
Presenter: Abhenil Mittal
Session: Poster session 07
2193P - Real-world evidence of the impact of immunotherapy (IT) on overall survival (OS) of patients (p) with malignant pleural mesothelioma (MPM) adjusted for tumor histology
Presenter: Susana Cedres Perez
Session: Poster session 07